Aptevo Therapeutics Inc(APVO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -57.76 | Insider Own | 5.81% | Shs Outstand | 1.8M | Perf Week | -16.77% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | 61.33% | Insider Trans | - | Shs Float | 1.7M | Perf Month | -23.86% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | -3.71 | Inst Own | 3.89% | Short Float | 5.68% | Perf Quarter | -66.08% |
| Income | -0.03B | P/S | - | EPS this Y | 80.47% | Inst Trans | 2.64% | Short Ratio | 1.01 | Perf Half Y | -72.76% |
| Sales | 0.00B | P/B | 0.31 | EPS next 5Y | 58.56% | ROA | -185.67% | Short Interest | 0.10M | Perf YTD | -85.79% |
| Book/sh | 4.26 | P/C | 0.25 | EPS past 3/5Y | - 89.05% | ROE | -445.43% | 52W High | -95.29% ($28.44) | Perf Year | -94.68% |
| Cash/sh | 5.42 | P/FCF | - | Sales past 3/5Y | - | ROIC | -299.9% | 52W Low | 6.99% ($1.25) | Perf 3Y | -100% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 99.41% | Gross Margin | - | Volatility(W/M) | 14% 6.87% | Perf 5Y | -100% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.12 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 2.08 | EPS Q/Q | 96.49% | Profit Margin | - | RSI (14) | 26.57 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.08 | Sales Q/Q | - | SMA20 | -17.43% ($1.62) | Beta | 1.65 | Target Price | $25.5 |
| Payout | - | Debt/Eq | 0.7 | Earnings | 2026/8/14 | SMA50 | -27.72% ($1.85) | Rel Volume | 0.3 | Prev Close | $1.36 |
| Employees | 36 | LT Debt/Eq | 0.54 | EPS/Sales Surpr. | 11.72% - | SMA200 | -69.32% ($4.37) | Avg Volume(3M) | 0.10M | Price | $1.34 |
| IPO | 2016/7/20 | Option/Short | No/Yes | Trades | 91 | Volume | 28,696 | Change | -1.47% |
🧬 Aptevo Therapeutics () is a US clinical-stage biotech developing targeted immuno-oncology therapies for blood cancers, including acute myeloid leukemia (AML), using its proprietary 'ADAPTIR' bispecific and trispecific antibody platform. Its lead candidate is Mipletamig, a CD123 x CD3 bispecific antibody that has reported high response rates and a favorable safety profile with no cytokine release syndrome (CRS) in newly diagnosed AML patients in the Phase 1b/2 RAINIER trial.
Over the past 1 year, on the lower side
95% below its 1-year high.
Traded less than usual. That is 30% of its average volume.
APVO has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +80.5% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 3.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #572 of 597 in the industry
Based on market cap of $2M.
DCOY#569 Decoy Therapeutics Inc $3M PER - 
CLDI#570 Calidi Biotherapeutics Inc $3M PER - 
HCWB#571 HCW Biologics Inc $2M PER - APVO#572 Aptevo Therapeutics Inc $2M PER - 
REVB#573 Revelation Biosciences Inc $2M PER - 
FAQ
What kind of company is APVO?
APVO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of APVO?
The market cap of APVO is approximately $2M, ranking 5,771 within its sector.
What is the 52-week high and low for APVO?
APVO has recorded a 52-week high of $28.44 and a low of $1.25.
